>> More News

CINCINNATI, Ohio -- January, 2007-- Celsus, Inc. announced plans to initiate phase I clinical studies of Intimatan™ while considering out- licensing opportunities for the major pharmaceutical markets.

Intimatan™ is an improved anti-inflammatory anticoagulant intended for use in indications dominated by heparin. Among its competitive advantages as a heparin-cofactor II agonist, Intimatan: (i) inhibits both systemic and clot-bound thrombin, the latter resistant to inhibition by the heparin-antithrombin complex; (ii) imparts an improved therapeutic index as demonstrated in high hurdle models of venous and arterial thrombosis; (iii) restores anticoagulant activity in antithrombin-deficient plasma of patients with both hereditary and acquired heparin resistance; (iv) blocks platelet activation in plasma of patients with heparin-induced thrombocytopenia (HIT) or "white clot syndrome", making Intimatan the first-in-class HIT- antagonist that abates the heparin-induced disease mechanism at its immunological root cause while affording anticoagulant and antithrombotic protection, and (v) reduces infarct size due to ischemia-reperfusion injury. In adjuvant settings, Intimatan shows synergy with glycoprotein IIb/IIIa inhibitors to yield complete myocardial protection in coronary arterial thrombosis models at signficantly reduced doses that diminish hemorrhagic effects, and prevents rethrombosis following successful fibrinolysis with recombinant tissue plasminogen activator. Protamine is an effective antidote for Intimatan as well as unfractionated heparin. There are no specific antidotes for low molecular weight heparin or the direct thrombin inhibitors, hirudin, lepirudin, bivalirudin and argatroban.

Celsus, Inc., a closely-held enterprise founded in 1987, has as its mission the manufacture of heparin derivatives and the development of novel carbohydrates for medical and biomedical needs unmet by heparin. Celsus Laboratories, Inc., its wholly-owned subsidiary, operates a U.S. Food and Drug Administration (FDA)-inspected bulk drug facility in Cincinnati and manufactures and markets more than a dozen heparin derivatives for use in products formulated for the prevention and treatment of thrombo-embolism, cardiac surgery, extracorporeal procedures, catheter lock-flush, blood-interacting medical devices, and affinity chromatograpy. It exports in excess of 50% of its manufacturing output and maintains heparin drug master file credentials with regulatory authorities in Australia, Canada, the European Union, Japan, and the United States. In anticipation of a generic Lovenox® / Clexane® low molecular weight heparin market, Celsus is finalizing a FDA drug master file for the active pharmaceutical ingredient, enoxaparin sodium. For more information about the company and its products, please visit www.celsuslaboratories.com.

Lovenox® and Clexane® are registered trademarks of Sanofi Aventis.

For additional information, contact: Cornelius L. Van Gorp (513) 772-8130

• 6/23/2005 - Celsus Laboratories granted european patent for dermatan disulfate.
• 2/28/2003 - Celsus qualifies for a third NIH grant for drug development.
• 1/6/2003 - Celsus Laboratories reemphasizes the integrity and safety of its heparins.
• 10/02/2002 - Combination of glycoprotein iib/iiia platelet receptor antagonist and heparin cofactor ii agonist receives notice of patent allowance.
• 9/3/2002 - Celsus receives research funding to develop o-desulfated heparin
• 1/23/2002 - New vascular imaging agent receives notice of allowance
• 2/23/2001 - Celsus receives NIH funding for development of new anticoagulant
• 10/10/2000 -Celsus process shown to eliminate transmissible spongiform encephalopathies
• 7/20/1999 - Celsus announces the issuance of u.s. patent dermatan disulfate intimatan
• 3/01/1999 - Celsus announces all animal-derived raw materials certified for absence of prion antigens
• 1/22/1999 - Intimax corporation to focus on the development of Intimatan
• 3/04/1997 - Celsus awarded patent to recover edible protein hydrolysate and heparin-like glycosaminoglycans